Chongqing Cancer Hospital
Chongqing Cancer Hospital
Chongqing, China7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2026-10-06 | NCT07347600 | |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-10-06 | NCT06084936 | |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05023980 | |
| Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2026-09-23 | NCT04662255 | |
| A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-09-03 | NCT04873362 | |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 / Phase 3 | 2026-07-28 | NCT06161025 | |
| A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-01-29 | NCT04965493 |